Evidence map›Paper›PMID 33367215›Full record

ArticleMayo Clinic proceedings. Innovations, quality & outcomes2020

Are Antimotility Agents Safe for Use in

Carla Kuon, Rae Wannier, David Sterken, Margaret C Fang, Jeffrey Wolf, Priya A Prasad

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Post-transplant diarrhea in pediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Carla KuonDivision of Hospital Medicine, University of California, San Francisco, San Francisco.
Rae WannierDivision of Hospital Medicine, University of California, San Francisco, San Francisco.
David SterkenDivision of Hospital Medicine, University of California, San Francisco, San Francisco.
Margaret C FangDivision of Hospital Medicine, University of California, San Francisco, San Francisco.
Jeffrey WolfDivision of Hospital Medicine, University of California, San Francisco, San Francisco.
Priya A PrasadDivision of Hospital Medicine, University of California, San Francisco, San Francisco.
San Francisco General Hospital · US

Funding

Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patientsK24HL141354 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FANG, MARGARET C. · 2018 to 2022
$731k
NHLBI NIH HHS K24 HL141354
6 · The paper itself

Abstract

objectivesTo evaluate the safety of antimotility agents (AAs) in a population of patients with hematologic malignancies and concurrent PATIENTS AND

methodsWe used the electronic health record to identify patients who were hospitalized in the adult malignant hematology service who had 1 or more toxin-positive

resultsThere were 339 patients who were stool toxin positive for CDI during the study period. Of those, 94 patients (27%) were prescribed AAs within 14 days of CDI diagnosis. All patients received CDI antimicrobial therapy within the first 24 hours. There were 2 adverse gastrointestinal events in the group that received AAs and 6 in the group that did not receive AAs. The risk of adverse events did not differ between patients who received AAs and those who did not (adjusted odds ratio, 0.36; 95% CI, 0.06 to 2.10). The mean age of the full cohort was 52.7±15.5 years, and the mean length of stay was 26.7±22.6 days. Early AA use (<48 hours of diagnosis) was not associated with increased adverse effects.

conclusionThere was no increase in the incidence of gastrointestinal events in the arm that used AAs compared with the control arm. The evidence suggests that for patients with hematologic malignancies and CDI, the addition of AAs to appropriate antimicrobial therapy poses no additional risk.

Indexed as

AA, antimotility agentCDI, Clostridioides difficile infectionEHR, electronic health recordHSCT, hematopoietic stem cell transplantICD-10, International Statistical Classification of Diseases, Tenth RevisionICD-9, International Classification of Diseases, Ninth RevisionIDSA, Infectious Disease Society of AmericaRR, relative riskUCSF, University of California, San Francisco

Identifiers

PMID33367215
PMCPMC7749233
OpenAlexW3094758678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.